What Procomil (Yohimbine) Treats: Main Uses and Benefits

The active ingredient, Yohimbine, is generally considered relevant for managing specific symptomatic patterns of erectile dysfunction (ED) in adult male patients, where purified Yohimbine may be part of symptomatic management in situations where supportive management is appropriate. The medication is considered relevant across conditions presenting with episodic or fluctuating manifestations of ED, particularly those categorized as nonorganic erectile dysfunction, and when additional management for discomfort or functional strain is required.

It is relevant for easing symptoms linked to physical discomfort and is applied in addressing symptomatic patterns of ED, such as the inability to achieve a firm erection or the inability to sustain an erection. The product plays a role in managing symptoms related to functional stress. It is often used during phases when symptoms become more noticeable, providing supportive relief when symptoms interfere with routine activities. It may assist with maintaining functional stability and supports general well-being during symptomatic phases.

---

Quick Fact: Relevant for Functional Strain Yohimbine is applied in scenarios where symptoms create noticeable functional strain related to erection quality and is considered relevant for managing milder presentations of ED.

Regulatory References

1. National Institutes of Health (NIH)

Who Can and Cannot Use Procomil (Yohimbine)?

Official regulatory guidelines strictly define the population eligible to use yohimbine hydrochloride, primarily restricting use to adult male patients who do not present with specific contraindications. Use is officially established only for this adult population.

Absolute Contraindications (Must Not Use)

Yohimbine is absolutely contraindicated and must not be used by individuals with the following pre-existing conditions:

• Cardiorenal Conditions: Hypertension, heart disease (e.g., angina pectoris), renal disease, and hepatic dysfunction.
• Neuropsychiatric Conditions: Anxiety, panic disorder, schizophrenia, or Post-Traumatic Stress Disorder (PTSD).
• Drug Interactions: Patients currently taking Monoamine Oxidase Inhibitors (MAOIs).

Age and Special Population Restrictions

Population Group	Eligibility Status	Basis
Pediatric Patients (Under 18)	Use Not Established	Safety and effectiveness have not been confirmed in this age group.
Geriatric Patients (Older Adults)	Not Recommended	Use is generally advised against due to safety considerations.
Pregnancy/Lactation	Contraindicated	Prohibited in pregnancy; requires discontinuation of nursing or medication during lactation.

Eligibility is also generally restricted for patients with a history of gastric or duodenal ulcers, or those with prostate conditions like Benign Prostatic Hyperplasia (BPH).

Procomil, which contains the active ingredient Yohimbine, has officially documented interaction patterns that are classified by regulatory agencies based on both pharmacokinetic and pharmacodynamic conflicts.

Contraindicated Combinations and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) and Sympathomimetic Stimulant Drugs (such as certain amphetamines) is contraindicated. These combinations are prohibited due to the high risk of additive sympathetic effects, which regulatory documents state can lead to severe adverse reactions like hypertensive crisis. The official prescribing information also explicitly lists Mavorixafor as a prohibited co-administered medicine. A formal timing-based rule requires a defined separation period (often 14 days) between using Yohimbine and these contraindicated agents.

Pharmacodynamic and Metabolic Effects

Yohimbine can cause pharmacodynamic antagonism with Antihypertensive Agents (e.g., Clonidine), potentially diminishing their effect. Regulatory documents note that Yohimbine may act as a CYP2D6 inhibitor. This metabolic effect can result in the increased plasma concentration of other co-administered medications that are CYP2D6 Substrates. Furthermore, using Yohimbine with Alcohol or Tyramine-rich foods may increase the risk of certain adverse effects.

Population-Specific Restrictions

The official prescribing information includes restrictions concerning specific patient populations. The use of Yohimbine is explicitly contraindicated in patients with renal impairment. Additionally, the drug's effects may be increased in patients with liver disease due to documented slower systemic clearance.

Targeted Blockade of Inhibitory alpha2 Adrenergic Receptors

Yohimbine's primary mechanism involves the competitive antagonism of presynaptic alpha2 adrenergic receptors on sympathetic nerve endings. By occupying these receptors, the drug functionally abolishes the normal negative feedback mechanism that normally constrains the release of the stimulating neurotransmitter norepinephrine (NE). This specific molecular interaction serves as the initiating step for the molecule's downstream physiological effects.

Disinhibition and Amplification of Sympathetic Signaling

The resulting functional disinhibition significantly elevates NE concentration in the synaptic clefts of both the central and peripheral nervous systems. This increased NE concentration leads to amplified activation of postsynaptic alpha1 and beta receptors, initiating a systemic sympathoexcitation. This enhancement in nerve signaling and the resulting modulation of localized vascular smooth muscle tone are the systemic and localized physiological consequences.

Official Administration Guidelines for Yohimbine

The administration of pharmaceutical-grade Yohimbine hydrochloride involves a standardized approach to its use.

Administration Scope	Official Instruction
Route of Administration	The preparation is for oral intake, typically as a tablet or capsule form
Standard Dosing Schedule	The usual adult dose is 5.4 mg taken three times a day. If initial intolerance occurs, the starting dose may be reduced to 2.7 mg three times daily, followed by a gradual titration to the usual dose.
Frequency Pattern	The drug is to be taken three times a day (TID) to maintain a consistent administration schedule.

---

Dosing Instructions and Population Constraints

The frequency and dose define a scheduled pattern of use that requires consistency throughout the day. If a dose is missed, it should be taken as soon as possible; however, if it is almost time for the next scheduled dose, the missed dose must be skipped. Doses should not be doubled to compensate for a missed dose.

Specific constraints on use exist for certain populations. Administration is contraindicated in patients with renal disease due to usage risks. Furthermore, safety and effectiveness have not been established for pediatric patients under 18 years of age, and use is generally discouraged in geriatric patients. The decision to discontinue therapy is typically based on a lack of observed response over the course of treatment.

Procomil (Yohimbine): Recent Clinical Evidence

Evidence for Use in Erectile Dysfunction (ED)

The research for Yohimbine, the active ingredient in Procomil, was examined in studies focusing on symptoms of erectile dysfunction (ED), primarily through short-term, placebo-controlled Randomized Controlled Trials (RCTs) and Systematic Reviews. Studies examined adult male patients, exploring changes in sexual function via patient self-reporting and objective assessments like penile rigidity. Aggregated data describe patterns observed in function compared to placebo treatments; however, the overall evidence is characterized by short follow-up durations.

Evidence in Different Etiologies

Research has explored how observed patterns might differ depending on the root cause. Studies focused on psychogenic or nonorganic causes have generally reported different observed patterns than those focused on organic ED. Data for the organic subgroup remain insufficient, and findings indicate different patterns depending on the type of ED studied in the research setting.

Long-Term Studies and Follow-up Data

The research is limited to investigating short-term symptom changes over periods of only a few months. Long-term outcomes are not well characterized, as data on the persistence of observed outcomes beyond the study period remain insufficient. The studies provide context on short-term changes, but limited information is available for understanding the effects of extended use.

Evidence Gaps and Areas of Uncertainty

The evidence base is limited by modest sample sizes, and data for specific groups like individuals with severe ED or complex comorbidities remain insufficient. Furthermore, the evidence quality varies across studies, leading to limited certainty in the broader landscape. Reports show that findings were mixed in certain subgroups, and comparative evidence is lacking for certain questions. Overall certainty remains low due to these research limitation frames.

Key Studies & References

1. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized controlled trials.
2. Yohimbine (StatPearls)

Common questions about Procomil (Yohimbine) (FAQ)

---

Q: Is Procomil a stimulant, and will it make me feel jittery or anxious?

While Yohimbine is not formally classified as a typical stimulant, its mechanism of action involves enhancing nerve signaling, a process called sympathoexcitation. Official information states that this action may cause common side effects such as nervousness, anxiety, and tremor (shaking).

---

Q: How long do the therapeutic effects of a single dose of Procomil typically last?

Pharmacokinetic data in regulatory references indicate the drug has a short elimination half-life, which is often cited as ranging from 0.25 to 2.5 hours. This pharmacokinetic parameter measures the time it takes for half of the drug to be cleared from the body.

---

Q: What are the most common mild side effects reported by users of Procomil?

Commonly documented adverse reactions include feelings of nervousness or anxiety, tremor (shaking), and headache. Cardiovascular effects like increased blood pressure and tachycardia (fast heartbeat) are also frequently reported in official product information.

---

Q: Does Procomil interact with antidepressant medications like SSRIs or MAOIs?

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is explicitly contraindicated (prohibited). Official product information also notes that combining Yohimbine with other classes of antidepressants, such as Tricyclic Antidepressants, may increase the risk of certain side effects like shakiness and anxiety.

---

Q: Can Procomil be taken alongside medications for ADHD or stimulants?

Co-administration with any medication classified as a Sympathomimetic Stimulant Drug is contraindicated (prohibited). This is due to the risk of additive sympathetic effects, which can lead to serious adverse reactions.

---

Q: Can consuming alcohol while taking Procomil increase the risk of side effects?

Official warnings state that using Yohimbine concurrently with ethanol (alcohol) may increase the potential for certain side effects.

---

Q: Are there specific foods or beverages, like those high in Tyramine, that should be avoided with Procomil?

Official warnings advise avoiding taking this medicine concurrently with foods rich in tyramine.

---

Q: Can Procomil cause dizziness or affect a person's ability to drive?

Regulatory documents indicate this medication may cause dizziness and/or affect a person's mood. Caution may be necessary if performing activities like driving or operating machinery.

---

Q: Is there a concern about Procomil affecting sleep or causing insomnia?

Insomnia (difficulty sleeping) is explicitly listed among the common adverse effects in regulatory safety documents.

---

Q: Is Procomil considered safe for older men (e.g., over 65)?

Official guidelines generally advise against use in older adults (geriatric patients). This is because this population is noted as having increased sensitivity to the potential cardiovascular and neurological adverse reactions of the compound.

---

Q: Are there any known long-term safety concerns associated with using Procomil?

Official regulatory evidence on the drug’s effects is primarily based on short-term clinical trials. Long-term outcomes and the persistence of observed results are not well characterized, and data on extended use are noted as insufficient in the evidence base.

---

Q: Does Procomil have an interaction with any common pain relievers (e.g., NSAIDs)?

Official drug interaction information notes that the risk of hypertension can be increased when Yohimbine is combined with certain common pain relievers.

---

Q: Is the source of Yohimbine (synthetic vs. natural bark extract) important for its effects?

The pharmaceutical product contains the purified salt, Yohimbine hydrochloride. Regulatory bodies note that the effects of the purified pharmaceutical salt may differ from unstandardized, over-the-counter bark preparations.

---

Q: How do the effects of Procomil compare to a placebo in clinical trials?

Clinical trials, as summarized in the regulatory context, suggest the drug supports physiological sexual function compared to an inactive placebo. However, the overall certainty of the evidence base is noted as low.

---

Q: If I have a history of stomach ulcers, is Procomil still an option?

Official prescribing information indicates that the use of Yohimbine is generally restricted or advised against for patients who have a history of gastric or duodenal ulcers.

---

Q: Does Procomil's effectiveness depend on the underlying cause of the sexual dysfunction?

Research reviewed in the regulatory context suggests that the patterns of observed change might differ depending on whether the underlying cause is classified as psychogenic or organic in nature. Data for the organic subgroup remain insufficient for a definitive conclusion.

---

Q: Is there any evidence to suggest Procomil can make symptoms of PTSD or Schizophrenia worse?

The drug is explicitly contraindicated in patients with a history of Schizophrenia, PTSD, Anxiety, or Panic Disorder. This is because the drug is known to produce symptoms like anxiety and tenseness.

How to Store and Dispose of Procomil (Yohimbine)

Official regulatory guidelines define specific conditions for storing and discarding Yohimbine to maintain product stability and ensure safety.

Storage and Protection

Requirement	Official Instruction
Temperature	Store at room temperature; keep away from heat and do not freeze.
Environment	Keep the medicine in a tightly closed container, protected from moisture and direct light.
Safety	The medicine must be kept out of the reach of children (often specified as store locked up).

Disposal

• Do not flush unused or expired Yohimbine down the toilet or pour it into a drain.
• Properly discard the product when it is no longer needed.
• Consult a pharmacist or local waste disposal service for the mandated method of discarding the contents and container, as the bulk substance is classified with strict acute toxicity and handling requirements.